摘要
Abstract
AIM To evaluate systematically the efficacy and safety of bevacizumab combined with paclitaxels in the treatment of platinum-resistant recurrent ovarian cancer(PROC).METHODS PubMed,Cochrane Library,CNKI,VIP,Wanfang database for randomized controlled clinical trials(RCTs)of comparing bevacizumab combined paclitaxels with paclitaxels alone in the treatment of PROC from database establishment to June 2022 were searched.Meta-analysis was performed using RevMan5.4 software provided by Crochran Collaboration,and the odds ratio(OR)and 95％confidence interval(CI)were calculated.RESULTS A total of 11 RCTs with 886 patients were included.Meta-analysis showed that the complete response rate(OR=2.07,95％CI:1.46～2.94,P＜0.000 1),partial response rate(OR=1.53,95％CI:1.16～2.02,P=0.002),overall response rate(OR=2.95,95％CI:2.15～4.04,P＜0.000 01),median progression-free survival(mPFS)and median overall survival(mOS)in bevacizumab combined with paclitaxels group(treatment group)were better than those in the simple paclitaxels group(control group),and the difference was statistically significant(P＜0.05).Among the common adverse reactions,the incidence of hypertension(OR=2.11,95％CI:1.03～4.31,P=0.04)and neutropenia(OR=2.18,95％CI:1.23～3.89,P=0.008)in the bevacizumab combined with paclitaxel chemotherapy group(treatment group)were higher than those in control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions such as gastrointestinal reactions(nausea and vomiting),proteinuria,bleeding,peripheral neuropathy,and thrombocytopenia between 2 groups(P>0.05).CONCLUSION In the treatment of PROC,the combination of bevacizumab and paclitaxels can improve clinical efficacy,mPFS and mOS compared with paclitaxels alone,and the safety is good and worthy of clinical popularization.However,it is also necessary to pay attention to the risk of hypertension,neutropenia.关键词
贝伐珠单抗/紫杉醇/复发性卵巢癌/铂耐药/Meta分析Key words
bevacizumab/paclitaxels/recurrent ovarian cancer/platinum resistance/Meta-analysis
